Nicolas Wisniacki

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

Xavier Mariette, Francesca Barone, Chiara Baldini et al. · JCI Insight · 2022 · 108 citations · Full text

Immunology, Ii Study, Immunotherapy +19

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis

Nicolas Wisniacki, Lakshmi Amaravadi, Gerald R. Galluppi et al. · Clinical Therapeutics · 2013 · 69 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Bart Keymeulen, André van Maurik, João J. Oliveira et al. · Diabetologia · 2020 · 47 citations · Full text

<i>In vivo</i> affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody

Juliet Reid, Stefano Zamuner, Ken Edwards et al. · British Journal of Clinical Pharmacology · 2018 · 45 citations · Full text

The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis

Grace Marden, Qi Wan, Jonathan A. Wilks et al. · Arthritis Research & Therapy · 2020 · 36 citations · Full text